APTIOM Drug Patent Profile

« Back to Dashboard

Which patents cover Aptiom, and when can generic versions of Aptiom launch?

Aptiom is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in APTIOM is eslicarbazepine acetate. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aptiom

A generic version of APTIOM was approved as eslicarbazepine acetate by DR REDDYS on June 29^th, 2021.

Summary for APTIOM

US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	568
Drug Prices:	Drug price information for APTIOM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for APTIOM
What excipients (inactive ingredients) are in APTIOM?	APTIOM excipients list
DailyMed Link:	APTIOM at DailyMed

See drug prices for APTIOM

Recent Clinical Trials for APTIOM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sunovion	Phase 3
Stanford University	Phase 4
Sunovion	Phase 4

See all APTIOM clinical trials

Pharmacology for APTIOM

Mechanism of Action	Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for APTIOM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
APTIOM	Tablets	eslicarbazepine acetate	200 mg, 400 mg, 600 mg and 800 mg	022416	7	2017-11-08

US Patents and Regulatory Information for APTIOM

APTIOM is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-004	Nov 8, 2013	AB	RX	Yes	Yes			Y
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-004	Nov 8, 2013	AB	RX	Yes	Yes				Y
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-004	Nov 8, 2013	AB	RX	Yes	Yes			Y
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-001	Nov 8, 2013	AB	RX	Yes	No
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013	AB	RX	Yes	No
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013	AB	RX	Yes	No				Y

Expired US Patents for APTIOM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-002	Nov 8, 2013
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-001	Nov 8, 2013
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-001	Nov 8, 2013
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013

EU/EMA Drug Approvals for APTIOM

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
BIAL - Portela & Ca, S.A.	Zebinix	eslicarbazepine acetate	EMEA/H/C/000988Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.	Authorised	no	no	no	2009-04-21
BIAL - Portela Ca, S.A.	Exalief	eslicarbazepine acetate	EMEA/H/C/000987Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.	Withdrawn	no	no	no	2009-04-21

International Patents for APTIOM

When does loss-of-exclusivity occur for APTIOM?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Cyprus

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering APTIOM around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	055939	METODOS PARA PREPARAR COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN ACETATO DE ESLICARBAZEPINA Y METODOS DE USO
Australia	2005331690	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
Brazil	PI0520258	uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
Canada	2607427	PROCEDES DE PREPARATION DE COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE L'ACETATE D'ESLICARBAZEPINE ET PROCEDES D'UTILISATION CORRESPONDANTS (METHODS OF PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING ESLICARBAZEPINE ACETATE AND METHODS OF USE)
Mexico	2007013882	METODOS PARA PREPARAR COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN ACETATO DE ESLICARBAZEPINA Y METODOS DE USO. (METHODS OF PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING ESLICARBAZEPINE ACETATE AND METHODS OF USE.)
Mexico	366496	METODOS PARA PREPARAR COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN ACETATO DE ESLICARBAZEPINA Y METODOS DE USO. (METHODS OF PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING ESLICARBAZEPINE ACETATE AND METHODS OF USE.)

Supplementary Protection Certificates for APTIOM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0751129	SPC027/2009	Ireland		SPC027/2009: 20091119, EXPIRES: 20210627
0751129	CA 2009 00023	Denmark
0751129	C300406	Netherlands		PRODUCT NAME: ESLICARBAZEPINE, DESGEWENST IN; REGISTRATION NO/DATE: EU/1/09/514/001-020 20090421
0751129	09C0040	France		PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421
0751129	SPC/GB09/047	United Kingdom		PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTERED: UK EU/1/09/514/001 20090421; UK EU/1/09/514/002 20090421; UK EU/1/09/514/003 20090421; UK EU/1/09/514/004 20090421; UK EU/1/09/514/005 20090421; UK EU/1/09/514/006 20090421; UK EU/1/09/514/019 20090421; UK EU/1/09/514/020 20090421; UK EU/1/09/514/013 20090421; UK EU/1/09/514/014 20090421; UK EU/1/09/514/015 20090421; UK EU/1/09/514/016 20090421; UK EU/1/09/514/017 20090421; UK EU/1/09/514/018 20090421; UK EU/1/09/514/007 20090421; UK EU/1/09/514/008 20090421; UK EU/1/09/514/009 20090421; UK EU/1/09/514/010 20090421; UK EU/1/09/514/011 20090421; UK EU/1/09/514/012 20090421
0751129	360	Finland

Aptiom Market Dynamics, Patent Exposure, Generic Competition, and Financial Trajectory

Last updated: September 17, 2026

Aptiom, the branded epilepsy drug containing eslicarbazepine acetate, has moved from a differentiated focal-seizure product to a mature anti-seizure medicine exposed to generic competition. Sunovion Pharmaceuticals, a subsidiary of Sumitomo Pharma, developed and commercialized Aptiom in the United States. FDA approval came in November 2013 for adjunctive treatment of partial-onset seizures in adults, followed by expanded labeling for patients two years and older.

The commercial outlook is constrained by generic entry, limited differentiation within the anti-seizure market, and the absence of a durable biologic-style exclusivity barrier. Brand revenue declined from its earlier peak as generic eslicarbazepine acetate products entered the U.S. market. Patent protection remains relevant to formulation and method-of-use litigation, but it is unlikely to preserve broad branded pricing once approved generics obtain market access.

What is Aptiom and how does it work?

Aptiom is the brand name for eslicarbazepine acetate, an oral anti-seizure medicine. It is converted in the body primarily to eslicarbazepine, which modulates voltage-gated sodium channels. The drug is marketed as an adjunctive treatment for focal-onset seizures.

Attribute	Aptiom
Active ingredient	Eslicarbazepine acetate
Dosage form	Oral tablets
Initial FDA approval	November 8, 2013
Original sponsor	Sunovion Pharmaceuticals
Current corporate owner	Sumitomo Pharma
Therapeutic area	Epilepsy and seizure disorders
Initial indication	Adjunctive treatment of partial-onset seizures in adults
Expanded pediatric use	Patients aged 2 years and older
Primary competitors	Vimpat, Briviact, Keppra, generic lacosamide, generic levetiracetam, generic oxcarbazepine

Aptiom was positioned against older sodium-channel agents such as carbamazepine and oxcarbazepine, while competing commercially with newer products including lacosamide and brivaracetam.

When did Aptiom receive FDA approval and exclusivity?

FDA approved Aptiom in 2013 under the conventional new drug application pathway. The product received five years of new chemical entity exclusivity, subject to the applicable statutory rules, together with pediatric exclusivity associated with subsequent pediatric development.

The initial exclusivity period did not prevent all later patent litigation because patent rights extended beyond regulatory exclusivity. FDA regulatory exclusivity and patent protection operated on separate timelines.

FDA milestone	Date
Original FDA approval	November 8, 2013
Pediatric indication expansion	2017
Pediatric exclusivity impact	Extended applicable patent and regulatory periods by six months where legally available
Generic approval period	Began after the relevant patent and regulatory barriers were addressed

FDA labeling identifies eslicarbazepine acetate as an approved treatment for focal-onset seizures, but does not give Aptiom an orphan-drug commercial position. Epilepsy is a large therapeutic category with substantial generic substitution.

What patents protect Aptiom?

Aptiom has been protected by composition, formulation, pharmaceutical-composition, and method-of-use patents. The principal U.S. patent estate extended beyond the five-year new chemical entity exclusivity period.

Public patent records identify U.S. Patent No. 8,338,485 as a key Aptiom-related patent with an expiration date in 2027, subject to statutory patent-term adjustment and pediatric exclusivity calculations. Other patents and patent-family members have covered dosage forms, treatment methods, and pharmaceutical compositions. The complete Orange Book position must be reviewed against the current FDA listing because listed patents can change through delisting, expiration, or patent-term adjustments.

Protection category	Commercial relevance
Active-ingredient and composition patents	Protect the eslicarbazepine acetate product and related compositions
Formulation patents	Can limit specific tablet formulations or release characteristics
Method-of-use patents	Can cover treatment of focal-onset seizures, dosing, or patient populations
Regulatory exclusivity	Delayed certain ANDA activity during the statutory exclusivity period
Pediatric exclusivity	Added six months to eligible patent and regulatory periods

The practical strength of the estate is lower than the nominal number of patents suggests. A generic applicant can challenge patents selectively and may obtain approval after invalidating, avoiding, or settling around specific claims.

What is the Orange Book status of Aptiom?

Aptiom is listed in the FDA Orange Book as a prescription tablet product. The Orange Book identifies patents and exclusivity information relevant to abbreviated new drug applications. Generic applicants use those listings to determine whether to file Paragraph IV certifications or pursue approval after patent expiry.

The core commercial question is whether an Orange Book-listed patent blocks approval of an ANDA. A patent listing can trigger a 30-month stay when the brand sponsor brings a timely infringement action following a Paragraph IV notice, although the stay can end earlier under certain statutory conditions.

The Orange Book does not guarantee that listed patents will survive litigation. It also does not prevent a generic applicant from developing a non-infringing product or challenging patent validity.

Which companies have challenged Aptiom patents?

Generic pharmaceutical companies have pursued eslicarbazepine acetate opportunities through ANDAs. Publicly reported generic activity has included applicants such as Dr. Reddy's Laboratories and other manufacturers seeking approval for eslicarbazepine acetate tablets.

Paragraph IV activity typically creates one of three outcomes:

1. Patent litigation and delayed approval.
2. A settlement allowing launch on an agreed date.
3. A non-infringement or invalidity position that produces earlier market entry if the generic prevails.

The commercial impact depends on whether the generic receives first-filer status, whether multiple ANDAs are approved simultaneously, and whether the parties agree to an authorized-generic arrangement.

What patent litigation affects Aptiom?

Aptiom-related litigation has centered on the standard ANDA dispute structure. Sunovion and affiliated entities have asserted patents against generic applicants seeking FDA approval for eslicarbazepine acetate tablets.

The key legal issues in these cases generally include:

• Whether the ANDA product infringes listed formulation or composition claims.
• Whether the asserted claims are invalid for anticipation or obviousness.
• Whether the patent claims cover the generic product as described in the ANDA.
• Whether settlement terms permit a defined generic launch date.
• Whether pediatric exclusivity or patent-term adjustments extend the effective barrier.

The litigation risk is highest when the brand relies on a small number of broad, unexpired patents. Risk falls when generic applicants can avoid the asserted claims through alternative formulations or when later patents contain narrow treatment or dosing claims.

What are Aptiom’s generic launch risks?

The principal risk is rapid price erosion after multiple generic approvals. Anti-seizure medicines are frequently substituted through pharmacy and payer channels, particularly when the generic has the same dosage form and strength.

Generic launch scenarios

Scenario	Likely commercial effect
Single generic or authorized generic	Moderate initial erosion; brand may retain specialty or physician-driven demand
Several simultaneous generics	Rapid loss of prescription volume and pricing power
First-filer exclusivity	Temporary limited competition followed by sharper erosion after exclusivity ends
Settlement with delayed entry	Preserves brand revenue until the agreed launch date
Patent invalidation before expiry	Accelerated generic entry and steep revenue decline
Narrow formulation patent survives	Some delay, but limited protection against alternative products

Aptiom's risk is greater than that of products requiring complex biologic manufacturing or device-specific delivery systems. Eslicarbazepine acetate is a chemically synthesized small molecule. Manufacturing complexity is therefore unlikely to create a durable barrier after ANDA approval.

How strong is the Aptiom patent estate?

Aptiom has a moderate patent position rather than a high-barrier estate.

Strengths include the product's multiple patent categories and the ability to assert patents in ANDA litigation. The estate also benefited from patent protection extending well beyond initial FDA approval.

Weaknesses include the small-molecule nature of the drug, the availability of conventional tablet manufacturing, competitive therapeutic substitutes, and the likelihood that generic applicants can target specific claims rather than challenge the entire estate. Method-of-use patents may have limited commercial value when generic labels omit protected language or when physicians prescribe the product for an indication supported by established clinical practice.

The estate is strongest before the first generic launch. Its economic value falls quickly once several approved generic suppliers establish substitutable supply.

What formulations are protected by Aptiom patents?

Aptiom is marketed in immediate-release oral tablets. Patent protection has related to pharmaceutical compositions, dosage forms, and treatment methods rather than a technically complex delivery platform.

The product does not depend on an injectable device, depot technology, transdermal system, or biologic manufacturing process. That limits the potential value of formulation patents compared with products protected by extended-release technologies or proprietary delivery systems.

The commercial relevance of a formulation patent depends on claim scope. A patent directed to a specific excipient combination or tablet characteristic may be avoidable if a generic can use a different formulation while meeting FDA bioequivalence requirements.

What is Aptiom’s financial trajectory?

Aptiom generated meaningful revenue for Sunovion during the years after launch, but it remained smaller than Sunovion's leading product, Latuda. The product benefited from growth in focal-seizure treatment and physician adoption of a once-daily sodium-channel therapy. Its financial trajectory later flattened as the epilepsy market became more competitive and generic alternatives expanded.

After generic entry, the primary financial variables became:

• The number of approved generic suppliers.
• Net price after rebates and discounts.
• Payer formulary placement.
• Brand retention among patients stabilized on Aptiom.
• The timing of patent settlements and generic launches.
• The cost of maintaining sales, medical-affairs, and market-access infrastructure.

Sumitomo Pharma reports product and regional financial information at the corporate segment level, but public annual reports do not consistently provide a current, standalone Aptiom revenue series. This limits precise year-by-year valuation of the product after generic competition intensified.

Revenue exposure

Aptiom is no longer comparable to a high-growth launch product. Its revenue is exposed to:

• Volume substitution by generic eslicarbazepine acetate.
• Therapeutic substitution to lacosamide, levetiracetam, brivaracetam, and oxcarbazepine.
• Payer pressure on branded anti-seizure products.
• Reduced sales-force economics as annual brand revenue declines.
• Potential inventory and wholesaler effects around generic launch.

For Sumitomo Pharma, Aptiom is strategically less important than products with longer exclusivity or stronger growth profiles. For a generic manufacturer, the opportunity remains commercially attractive if multiple strengths can be supplied reliably and if market share is captured during the first approval cycle.

How does Aptiom compare with Vimpat, Briviact, and Keppra?

Product	Active ingredient	Market position	Generic exposure
Aptiom	Eslicarbazepine acetate	Focal-onset seizures; once-daily tablet positioning	High
Vimpat	Lacosamide	Focal-onset seizures; oral and intravenous options	High after patent expiry
Briviact	Brivaracetam	Newer focal-seizure therapy with branded positioning	Lower while exclusivity remains
Keppra	Levetiracetam	Broad, established anti-seizure use	Mature generic market
Trileptal	Oxcarbazepine	Older sodium-channel competitor	Mature generic market

Aptiom's differentiation is based mainly on dosing convenience, clinical positioning, and tolerability relative to older therapies. It lacks the exclusivity profile of a biologic and competes against several low-cost generic alternatives.

What licensing deals and corporate transactions affect Aptiom?

Aptiom was developed and commercialized by Sunovion, which became part of Sumitomo Pharma through Sumitomo Dainippon Pharma's acquisition of Sunovion's parent company. The product is therefore evaluated within Sumitomo Pharma's broader specialty and CNS portfolio.

The principal strategic issue is portfolio allocation. As Aptiom matures, the owner must balance continued brand support against investment in newer CNS assets. Licensing value is constrained by generic exposure and the limited ability to create a new exclusivity period without an improved formulation, combination product, or newly approved indication.

What is the outlook for Aptiom and generic launch timing?

Aptiom's U.S. outlook is a mature-brand decline followed by residual branded demand. The most likely long-term structure is a multi-source generic market with lower prices and reduced brand volume.

Patent expiry in or around the late 2020s remains relevant to residual listed claims, but commercial generic entry can occur earlier through Paragraph IV litigation, settlement, patent invalidation, or non-infringing product design. The exact launch date depends on the current Orange Book listings, litigation outcomes, FDA approvals, and any settlement restrictions.

Geographic protection is also uneven. U.S. patent rights do not control generic entry in Europe, Canada, Japan, or emerging markets. Each jurisdiction has separate patent, regulatory, and substitution rules. International Aptiom sales therefore face different launch schedules and price dynamics.

Key Takeaways

• Aptiom is eslicarbazepine acetate, an oral treatment for focal-onset seizures.
• FDA approved the product in November 2013.
• Sunovion developed Aptiom; Sumitomo Pharma is the corporate owner.
• The product has composition, formulation, and method-of-use patent protection, including a key patent publicly identified as U.S. Patent No. 8,338,485.
• Generic competition is the dominant long-term market risk.
• Aptiom is a small-molecule tablet, so manufacturing complexity is unlikely to block generic substitution.
• Brand revenue has moved from growth to maturity and decline.
• Patent litigation and Paragraph IV challenges determine the timing of competitive entry.
• Multiple approved generics would produce rapid price erosion and lower brand prescription volume.
• Aptiom has a moderate patent estate but lacks the durable barriers associated with biologics or complex delivery systems.

FAQs About Aptiom Market and Patent Risk

Is Aptiom the same as oxcarbazepine?

No. Aptiom contains eslicarbazepine acetate, while oxcarbazepine is the active ingredient in Trileptal and its generic equivalents. The drugs are related sodium-channel therapies but are not the same product.

Can a patient switch from Aptiom to generic eslicarbazepine acetate?

A pharmacist may substitute an FDA-approved generic where state law and payer rules permit. Prescribers may consider dose, tolerability, seizure control, and patient-specific factors before switching.

Does Aptiom have orphan-drug exclusivity?

No. Aptiom was approved for focal-onset seizures and does not have the orphan-drug exclusivity framework associated with an orphan indication.

Are Aptiom patents enforceable outside the United States?

U.S. Aptiom patents apply only in the United States. Patent protection in other countries depends on national or regional patent filings, grants, term adjustments, and validity.

What would most reduce Aptiom’s residual brand value?

The largest factors would be approval of several generic suppliers, loss of favorable formulary placement, a broad patent invalidation, or a settlement that permits earlier generic launch.

References

1. U.S. Food and Drug Administration. (2013). FDA approves Aptiom to treat seizures associated with epilepsy.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Aptiom (eslicarbazepine acetate) prescribing information. Sunovion Pharmaceuticals Inc.
4. U.S. Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 8,338,485.
5. Sumitomo Pharma Co., Ltd. (2024). Annual report and financial results materials.
6. Sunovion Pharmaceuticals Inc. (2023). Aptiom product information and corporate materials.

DrugChatter Q&A for APTIOM

Who makes aptiom?
Aptiom generic name?
Aptiom discount?